Case reports showing complete remission after IFNα monotherapy in secondary AML following essential thrombocytosis and/or myelofibrosis may indicate that subsets of patients are particularly sensitive to IFNα (Berneman et al. 2010; Dagorne et al. 2013). This evidence concerns the gene IFNA1 and myelofibrosis.